BioCentury
ARTICLE | Financial News

Inovio raises $75M in follow-on

July 21, 2017 8:33 PM UTC

On July 19, Inovio Pharmaceuticals Inc. (NASDAQ:INO) raised $75 million through the sale of 12.5 million shares at $6 in a follow-on underwritten by Citigroup, Piper Jaffray, RBC Capital Markets, H.C. Wainwright, Maxim Group, Aegis Capital, and the National Securities Corp. subsidiary of National Holdings Inc. (NASDAQ:NHLD).

On June 8, Inovio gained 11% after FDA lifted a clinical hold on its Phase III program of VGX-3100 to treat cervical dysplasia caused by HPV. Inovio spokesperson Jeff Richardson told BioCentury the company has begun Phase III trials of the candidate (see BioCentury, June 9)...

BCIQ Company Profiles

Inovio Pharmaceuticals Inc.